BerGenBio ASA: Invitation to First Quarter 2018 Results Presentation and Webcast

Bergen, Norway, 08 May 2018- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing bemcentinib (BGB324), a first-in-class selective small molecule AXL inhibitor, as a potential cornerstone therapy for multiple cancer indications, will announce its results for the first quarter 2018 on Tuesday, 15 May 2018. A presentation by BerGenBio's senior management team will take place at 10:00 am CET at: 

Felix Konferansesenter, Bryggetorget 3, 0125 Oslo 

The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Financial Reports. A recording will be available shortly after the webcast has finished. 

The results report and presentation will be available at www.bergenbio.com in the section: Investors/Financial Reports from 7:00 am CET the same day.

-Ends-

Contacts

Richard Godfrey

CEO, BerGenBio ASA 

ir@bergenbio.com

+47 917 86 304 

Rune Skeie

CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

Media contacts

David Dible, Mark Swallow, Marine Perrier 

Citigate Dewe Rogerson 

bergenbio@citigatedr.co.uk

+44 207 638 9571 

Forward looking statements 

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

About Us

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths. Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create important new therapeutic options for cancer patients.

Subscribe